{"url":"https://lda.senate.gov/api/v1/filings/b0d8de59-60e5-47eb-9dde-66bd0e0cdc8a/","filing_uuid":"b0d8de59-60e5-47eb-9dde-66bd0e0cdc8a","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2011,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/b0d8de59-60e5-47eb-9dde-66bd0e0cdc8a/print/","filing_document_content_type":"text/html","income":"5000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Donald \"Dack\" Dalrymple, Principal","dt_posted":"2011-07-13T14:36:04.327000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1926 N STREET NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":5073,"url":"https://lda.senate.gov/api/v1/registrants/5073/","house_registrant_id":34019,"name":"DALRYMPLE & ASSOCIATES, LLC","description":"Business Consulting","address_1":"1926 N Street, NW","address_2":"Suite 1","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20036","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DONALD \"DACK\" DALRYMPLE","contact_telephone":"+1 202-833-1043","dt_updated":"2022-04-06T16:04:33.500584-04:00"},"client":{"id":105002,"url":"https://lda.senate.gov/api/v1/clients/105002/","client_id":137,"name":"DISCOVERY LABORATORIES","general_description":"Biodefense & Civilian Drug Development","client_government_entity":false,"client_self_select":false,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-01-10"},"lobbying_activities":[{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Small peptide synthetic lung surfactant and delivery devices CBRN threat medical countermeasures research and development defense agency grant and contract funding opportunities, legislation, appropriations and oversight.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":46869,"prefix":"mr","prefix_display":"MR.","first_name":"DONALD","nickname":"DACK","middle_name":null,"last_name":"DALRYMPLE","suffix":null,"suffix_display":null},"covered_position":"Principal","new":false}],"government_entities":[{"id":30,"name":"Army, Dept of (Other)"},{"id":115,"name":"Ballistic Missile Defense Organization"},{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":236,"name":"Defense Threat Reduction Agency (DTRA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"Small peptide synthetic lung surfactant and delivery device medical countermeasures research and development agency grant and contract funding opportunities, legislation, appropriations, and oversight.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":46869,"prefix":"mr","prefix_display":"MR.","first_name":"DONALD","nickname":"DACK","middle_name":null,"last_name":"DALRYMPLE","suffix":null,"suffix_display":null},"covered_position":"Principal","new":false}],"government_entities":[{"id":30,"name":"Army, Dept of (Other)"},{"id":115,"name":"Ballistic Missile Defense Organization"},{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":236,"name":"Defense Threat Reduction Agency (DTRA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Small peptide synthetic lung surfactant and medical device delivery medical countermeasures against CBRN threats research and development grant and contract funding opportunities, legislation, appropriations and oversight.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":46869,"prefix":"mr","prefix_display":"MR.","first_name":"DONALD","nickname":"DACK","middle_name":null,"last_name":"DALRYMPLE","suffix":null,"suffix_display":null},"covered_position":"Principal","new":false}],"government_entities":[{"id":30,"name":"Army, Dept of (Other)"},{"id":115,"name":"Ballistic Missile Defense Organization"},{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":236,"name":"Defense Threat Reduction Agency (DTRA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}